<DOC>
	<DOCNO>NCT02407756</DOCNO>
	<brief_summary>The primary objective study characterize safety pharmacokinetics ( PK ) dupilumab pediatric patient moderate-to-severe atopic dermatitis ( AD ) ( adolescent ≥12 &lt; 18 year age ) severe AD ( child ≥6 &lt; 12 year age ) . The secondary objective study explore immunogenicity efficacy dupilumab pediatric patient moderate-to-severe AD ( adolescent ≥12 &lt; 18 year age ) severe AD ( child ≥6 &lt; 12 year age ) .</brief_summary>
	<brief_title>A Study Determine Safety Tolerability Dupilumab ( REGN668/SAR231893 ) Patients Aged ≥6 &lt; 18 Years With Atopic Dermatitis ( Eczema )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Key 1 . Male female patient ≥6 &lt; 18 year age diagnosis 1 . Atopic Dermatitis whose disease adequately control topical medication 2 . Minimum disease severity , define Investigator 's Global Assessment ( IGA ) 1 . IGA = 3 4 adolescent ≥12 &lt; 18 year age 2 . IGA = 4 child ≥6 &lt; 12 year age Key 1 . Recent treatment ( within specific time window baseline visit ) systemic immunosuppressive agent eg . Systemic corticosteroid , live ( attenuate ) vaccine investigational drug include biologics 2 . History follow infection : 1 . Any systemic infection require treatment within 4 week baseline visit 2 . Superficial skin infection within 1 week baseline visit 3 . Known history HIV infection 4 . History seropositivity hepatitis B C screen test 5 . History clinical endoparasitosis ( ie , helminthic infection ) within 12 month baseline visit , high risk helminthic infection , unless subsequent medical assessment ( e.g . stool exam , blood test , etc . ) rule possibility parasite infection/infestation 3 . History malignancy within 5 year baseline visit 4 . Persistent ( confirm repeat test ≥2 week apart ) elevate transaminase ( alanine aminotransferase [ ALT ] and/or aspartate aminotransferase [ AST ] ) 3 time upper limit normal ( ULN ) screen period 5 . Presence severe concomitant illness ( e ) , investigator 's judgment , would adversely affect patient 's participation study 6 . Presence skin comorbidities may interfere study assessment 7 . Females patient pregnant breastfeed 8 . Female patient reproductive potential sexually active , unwilling use adequate method contraception</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Eczema</keyword>
</DOC>